In this article, we will discuss Arsenic Trioxide (Dosage Overview). So, let’s get started.
Arsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
Induction Treatment Schedule: Administer Arsenic Trioxide intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Do not exceed 60 doses for induction.
Consolidation Treatment Schedule: Begin consolidation treatment 3 to 6 weeks after completion of induction therapy. Administer Arsenic Trioxide intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5
Dose Adjustment for Non-Hematologic Adverse Reactions
If a severe non-hematologic adverse reaction occurs (such as neurologic or dermatologic toxicity), consider delaying Arsenic Trioxide infusion until the event has resolved (≤ Grade 1).